Top Markets
#1 DogBull DogBull +104.58%
#2 Siacoin Siacoin +51.37%
#3 ADO Protocol ADO Protocol +46.38%
#4 MarsCoin MarsCoin +44.35%
#5 UnifAI Network UnifAI Network +42.92%
#6 Magma Finance Magma Finance +28.97%
#7 Useless Coin Useless Coin +26.04%
#8 Ontology Gas Ontology Gas +20.36%
#9 Cash Cat Cash Cat +17.48%
#10 Apertum Apertum +14.63%
Coin of the day
DogBull DogBull
設定
言語
日本
通貨
USD
テーマ
Evommune, Inc. Evommune, Inc.

Evommune, Inc.

EVMN
株式のランク #13891
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
株価
$12.45
時価総額
$451.84M
変化（1日）
-1.39%
変化（1年）
-
国
US
取引 Evommune, Inc. (EVMN)

カテゴリー

Healthcare
Evommune, Inc.（EVMN）のEPS
2026 時点のEPS TTM: 0
Evommune, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Evommune, Inc.のEPS履歴（2026から2026まで）
各年末時点のEPS
年 EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH